Does Amniocentesis or CVS Increase the risk of HIV Vertical Transmission?
BACKGROUND AND PURPOSE:
Recent studies indicate minimal to no additional risk of HIV transmission if prenatal diagnostic testing is performed under treatment with effective combination regimens (highly active antiretroviral therapy, HAART)
Studies have small sample sizes
Floridia et al. (BJOG, 2016) sought to confirm these findings by analyzing larger cohorts of pregnant women with HIV to determine the relationship between invasive procedures and outcomes
National observational study of 2065 pregnant women with HIV
National Program on Surveillance on Antiretroviral Treatment in Pregnancy in Italy
Main outcomes were rate of invasive testing, intrauterine death, HIV transmission
5.5% of subjects had invasive tests performed
87.6% of procedures were conducted under antiretroviral treatment, with a significant increase over time in the proportion of tests performed under highly active antiretroviral therapy (HAART) reaching 100% from 2011-2015
Among 88 live births with either amniocentesis, CVS, or both, two HIV transmissions occurred
No transmission cases after 2005
One of the cases was a primary infection with HIV
No HIV transmission occurred among the women who were on HAART at the time of invasive testing
Invasive prenatal testing does not appear to increase the risk of HIV vertical transmission among pregnant women under suppressive antiretroviral treatment
Please sign up or log in to your ObGFirst to access this Premium Content
Media - Internet
Computer System Requirements
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan